Summary
During 1984 to 1986, 121 patients with gonorrhoea were treated with ofloxacin. This report is to summarize the results of our trial in patients treated with three different dose regimens of ofloxacin: A) a single 800 mg dose of ofloxacin (32 patients); B) a single 400 mg dose of ofloxacin (55 patients) or C) a twice a day dose of 600 mg ofloxacin (34 patients). In addition, 19 patients with urinary tract infection and eight patients with enteric fever were treated with 400 mg ofloxacin twice a day for seven to ten days. Out of 121 patients with gonococcal urethritis, only 107 patients were evaluable. Cure was obtained in 96.5%; 93.2% and 94.5% of the patients in groups A, B and C respectively. 16 out of 17 patients with urinary tract infection achieved clinical cure or improvement. The 16 patients were bacteriologically assessible; pathogens were eradicated in all of them. Ofloxacin was also effective in the treatment of enteric fever, in which eradication was achieved in all seven patients. 28% ofNeisseria gonorrhoea and 29% ofSalmonella spp. isolated in our community were β-lactamase-positive.
Zusammenfassung
Von 1984 bis 1986 wurden 121 an Gonorrhoe erkrankte Patienten mit Ofloxacin behandelt. Die Ergebnisse unserer mit drei verschiedenen Ofloxacindosierungen durchgeführten Studie werden im folgenden mitgeteilt. Dosierung A: Einzeldosis von 800 mg Ofloxacin (32 Patienten); Dosierung B: Einzeldosis von 400 mg Ofloxacin (55 Patienten); Dosierung C: 600 mg Ofloxacin zweimal täglich (34 Patienten). Außerdem wurden 19 Patienten mit Harnwegsinfektionen und acht Patienten mit Typhus für sieben bis zehn Tage mit 400 mg Ofloxacin zweimal täglich behandelt. Von den 121 Patienten mit Gonokokken-Urethritis konnten nur 105 ausgewertet werden. Bei 96,5% der Gruppe A, 93,2% der Gruppe B und 94,5% der Gruppe C wurde eine Heilung erzielt. 16 der 17 Patienten mit Harnwegsinfektionen wurden geheilt oder gebessert. Eine bakteriologische Kontrolluntersuchung bei 16 dieser Patienten ergab eine Eradikationsrate von 100%. Ofloxacin erwies sich auch als wirksam in der Typhustherapie. Bei allen sieben behandelten Patienten wurden die Erreger eliminiert. 28% der in unserem Krankengut isoliertenN. gonorrhoeae-Stämme und 29% derSalmonella spp. waren β-laktamasepositiv.
Similar content being viewed by others
Literature
Yamamoto, Y. Clinical studies on DL-8280 in male gonococcal urethritis. Japan J. Assoc. Infect. Dis. 588 (1984) 784–789.
Tanphaichitra, D., Sahaphong, S., Srimuang, S. Ofloxacin, a new quinolone or a new pyridone carboxylic acid, in the treatment of gonococcal urethritis. Recent advances in chemotherapy. University of Tokyo Press, Tokyo, Japan 3 (1985) pp. 2305–2306.
Hirano, S. Clinical evaluation of DL-8280 in urinary tract infections. Chemotherapy (Tokyo) 32 (Suppl. 1) (1984) 673–680.
Fujimura, N. Clinical efficacy of DL-8280 on urinary tract infection and urogenital infection. Chemotherapy (Tokyo) 32 (Suppl. 1) (1984) 716–724.
Kawabata, T. Fundamental and clinical studies on DL-8280 in urinary tract infection. Chemotherapy (Tokyo) 32 (Suppl. 1) (1984) 795–809.
Kiyota, H. Clinical evaluation of DL-8280 in urinary tract infections. Chemotherapy (Tokyo) 32 (Suppl. 1) (1984) 588–595.
Anderson, E. S., Smith, H. R. Chloramphenicol resistance in the typhoid bacillus. Br. Med. J. 3 (1972) 329–331.
Butler, T., Linh, N. N., Arnold, K., Pollack, M. Chloramphenicol resistant typhoid fever in Vietnam associated with R-factor. Lancet II (1973) 983–985.
Overturf, G., Marton, K. I., Mathies Jr, A. W. Antibiotic resistance in typhoid fever. Chloramphenicol-resistance among clinical isolates ofSalmonella typhi in Los-Angeles (1972). Epidemiological and bacteriological characteristics. N. Engl. J. Med. 289 (1973) 463–465.
Tanphaichitra, D. Cellular immunity in typhoid fever, legionnaires' disease, amoebiasis: role of transfer factor, and levamisole in typhoid fever. Int. Symp. Ent. Infect. Man Animals. Dev. Biol. Stand. 53 (1983) 35–40.
Tanphaichitra, D., Bussayanond, A., Christensen, O. The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever. J. Antimicrob. Chemother. 8 (1981) 23–28.
Tanphaichitra, D., Bussayanond, A., Christensen, O. The combination of pivmecillinam and pivampicillin compared to co-trimoxazole in the treatment of enteric fever. Infection 10 (1982) 82–84.
Pillay, N., Adams, E. B., North-Coombes, D. Comparative trial of amoxycillin and chloramphenicol in the treatment of typhoid fever in adults. Lancet II (1975) 333–334.
Tanphaichitra, D., Kanjanapanjapol, S., Srimuang, S., Robinson, O. P. W. Use of temocillin in typhoid fever, hepatobiliary disease and other infections. Drugs 29 (Suppl. 5) (1985) 201–205.
Gherunpong, V., Komolpit, T. Antibiotic resistance ofSalmonella typhi isolates at Siriraj hospital (1974). Siriraj Hospital Gazette 28 (1976) 523–536.
Tanphaichitra, D., Srimuang, S., Chaiprasittigul, P., Menday, P., Christensen, O. E. The combination of pivmecillinam and pivampicillin in the treatment of enteric fever. Infection 12 (1984) 381–383.
Tanphaichitra, D.: Ofloxacin, a new quinolone in the treatment of gonococcal urethritis. International Symposium on Quinolones. Oral presentation. Geneva, Switzerland. July 21 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tanphaichitra, D., Sahaphong, S. & Srimuang, S. Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections. Infection 14 (Suppl 4), S321–S323 (1986). https://doi.org/10.1007/BF01661308
Issue Date:
DOI: https://doi.org/10.1007/BF01661308